Kezar Life Sciences’ (KZR) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Kezar Life Sciences (NASDAQ:KZR) in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a $7.00 target price on the stock. HC Wainwright also issued estimates for Kezar Life Sciences’ Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($0.97) EPS, Q1 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.19) EPS and FY2025 earnings at ($0.82) EPS.

Kezar Life Sciences Stock Down 1.8 %

NASDAQ KZR opened at $0.61 on Wednesday. The stock’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.77. Kezar Life Sciences has a one year low of $0.54 and a one year high of $1.69. The firm has a market cap of $44.66 million, a PE ratio of -0.44 and a beta of 0.28. The company has a debt-to-equity ratio of 0.05, a current ratio of 11.48 and a quick ratio of 11.49.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Fidelis Capital Partners LLC bought a new position in Kezar Life Sciences in the 1st quarter worth approximately $25,000. Mackenzie Financial Corp bought a new stake in shares of Kezar Life Sciences during the second quarter worth $35,000. SG Americas Securities LLC lifted its stake in shares of Kezar Life Sciences by 33.8% during the fourth quarter. SG Americas Securities LLC now owns 43,950 shares of the company’s stock valued at $42,000 after acquiring an additional 11,109 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Kezar Life Sciences in the second quarter valued at about $63,000. Finally, Panagora Asset Management Inc. acquired a new stake in Kezar Life Sciences in the fourth quarter worth about $80,000. 67.90% of the stock is owned by institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.